Innovative approaches to novel antibacterial drug discovery

Current Opinion in Biotechnology

Volumn 8, Issue 6, 1997, Pages 757-762

  Trias, Joaquim ^a   Gordon, Eric M ^a  

^a Versicor Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BIOTECHNOLOGY; DRUG DEVELOPMENT; GENOME; PRIORITY JOURNAL; REVIEW;

EID: 0030723134     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(97)80131-0     Document Type: Article

References (57)

1. Chu DTW, Plattner JJ, Katz L. New directions in antibacterial research. of outstanding interest J Med Chem. 39:1996;3853-3874 The authors provide a thorough and broad overview of the current state of research in antibacterial disease. New work is placed within the context of the past several decades of the field.
2. Gold HS, Moellering RC. Antimicrobial-drug resistance. N Engl J Med. 335:1996;1445-1453.
3. Panlilio AL, Culver DH, Gaynes RP, Banerjee S, Henderson TS, Tolson JS, Martone WJ. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol. 13:1992;582-586.
4. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. of outstanding interest J Antimicrob Chem. 40:1997;135-136 This is the first report of an S. aureus methicillin resistant strain isolated from a patient that did not respond to vancomycin treatment. This strain had reduced susceptibility to the glycopeptide and the mechanism of resistance is different than that of enterococci.
5. Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis. 24:1997;S85-S88.
6. McDougal LK, Rasheed JK, Biddle JW, Tenover FC. Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States. Antimicrob Agents Chemother. 39:1995;2282-2288.
7. Falkow S. What is a pathogen? ASM News. 63:1997;359-365.
8. Fenner F. The effects of changing social organization on the infectious diseases of man. Boyden SV. The Impact of Civilisation on the Biology of Man. 1970;3-73 University of Toronto Press, Toronto.
9. Masur H. Management of opportunistic infections associated with HIV infection. Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. 1995;1280-1294 Churchill Livingstone, New York.
10. Feinberg MB. Changing the natural history of HIV disease. Lancet. 348:1996;239-246.
11. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? of special interest Lancet. 350:1997;430-436 A discussion of the current evidence for the link between cronary diseases and infections by C. pneumoniae and H. pylori.
12. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: a randomized, controlled study. Ann Intern Med. 116:1992;705-708.
13. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. of outstanding interest Lancet. 350:1997;404-407 This paper shows that coronary heart diseases associated to C. pneumoniae exposure can be treated with a macrolide antibiotic in a controlled trial and reduce mortality. The clinical trial results suggest that some cronary diseases can be treated with antibiotics.
14. Mishina D, Kastel P, Brown ST, Gilberts EC, Greenstein RJ. On the etiology of Crohn disease. Proc Natl Acad Sci USA. 93:1996;9816-9820.
15. Gallop MA, Barrett RW, Dower WJ, Fodor SPA, Gordon EM. Applications of combinatorial technologies to drug discovery. Part 1. Background and combinatorial peptide libraries. J Med Chem. 37:1994;1233-1251.
16. Gordon EM, Barrett RW, Dower WJ, Fodor SPA, Gallop MA. Applications of combinatorial technologies to drug discovery. Part 2. Combinatorial organic synthesis. Library screening strategies and future directions. J Med Chem. 37:1994;1385-1401.
17. Gordon EM, Gallop MA, Patel DV. Strategy and tactics in combinatorial organic synthesis. Applications to drug discovery. of outstanding interest Accounts Chem Res. 29:1996;144-154 Actual accounts of the preparation of small molecule combinatorial libraries for drug discovery applications.
18. Gordon EM. Applications of small molecule combinatorial chemistry to drug discovery. Drug Discov Today. 1:1996;134-144.
19. Ellman JA. Design synthesis and evaluation of small-molecule libraries. of outstanding interest Accounts Chem Res. 29:1996;132-143 This short review describes a significant body of seminal work from one of the leading research groups in the field.
20. Baldwin JJ, Henderson I. Recent advances in the generation of small molecule combinatorial libraries: encoded split synthesis and solid-phase synthetic methodology. Med Res Rev. 16:1996;391-405.
21. Murphy MM, Schullek JR, Gordon EM, Gallop MA. Combinatorial organic synthesis of highly functionalized pyrrolidines: identification of a potent angiotensin converting enzyme inhibitor from a mercaptoacyl proline library. J Am Chem Soc. 117:1995;7029-7030.
22. Ruhland B, Bandari A, Gordon EM, Gallop MA. Solid-supported combinatorial synthesis of structurally diverse β-lactams. of outstanding interest J Am Chem Soc. 118:1995;253-254 An early example of solid phase combinatorial organic synthesis of small molecules. The monocyclic β-lactam products are of clear relevance to infectious disease medicinal chemistry. Extension of this type of approach could lead to monobactam libraries.
23. MAGPIE on World Wide Web URL: http://www.mcs.anl.gov/home/gaasterl/genomes.html of outstanding interest.
24. This World Wide Web site has updated information on microbial and eukaryotic genome projects. It provides useful links to other sites for individual genomes and status of projects.
25. Browne MJ, Gloger IS, Hodgson JE, Robinson JH. The importance of genome analysis to the drug discovery process. Mol Med Today. 1:1995;371-377.
26. Lander ES. The new genomics: global views of biology. of special interest Science. 274:1996;536-539 This paper includes a thorough discussion on the application of genomics to drug discovery that can be applied to all therapeutic areas. The impact of genomic information on understanding gene expression and protein levels is also discussed.
27. Broach JR, Thorner J. High-throughput screening for drug discovery. of outstanding interest Nature. 384S:1996;14-16 The field of screening is presently quite dynamic as researchers seek to identify novel methodologies which exploit and integrate with the methods of combinatorial chemistry. This is a very good overview of the current state of thinking in the screening field.
28. Oldenburg KR, Vo KT, Ruhland B, Schatz PJ, Yuan Z. A dual culture assay for the detection of antimicrobial activity. of special interest J Biomol Screen. 1:1996;123-130 A one-pot growth assay for unrelated microorganisms was developed for screening large combinatorial libraries, the paper shows that it is possible to develop novel screening strategies which complement the formats of combinatorial library synthesis.
29. Nicolaou KC, Xiao XY, Parandoosh Z, Senyei A, Nova MP. Radiofrequency encoded combinatorial chemistry. Int Ed Angew Chem. 34:1995;2289-2290.
30. Spratt BG, Cromie KD. Penicillin-binding proteins of Gram-negative bacteria. Rev Infect Dis. 10:1988;699-711.
31. Chittum HS, Champney WS. Erythromycin inhibits the assembly of the large ribosomal subunit in growing Escherichia coli cells. Curr Microbiol. 30:1995;273-279.
32. Champney WS, Burdine R. 50S Ribosomal subunit synthesis and translation are equivalent targets for erythromycin inhibition in Staphylococcus aureus. Antimicrob Agents Chemother. 40:1996;1301-1303.
33. Champney WS, Burdine R. Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus. Antimicrob Agents Chemother. 39:1995;2141-2144.
34. Fourmy D, Recht MI, Blanchard SC, Puglisi JD. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. of outstanding interest Science. 274:1996;1367-1371 The RNA - paromycin structure was solved using NMR. This paper describes the interaction between the 30S ribosomal A-site and the aminoglycoside using NMR. This site can be used for the rational drug design of novel antibiotics.
35. Kadurugamuwa JL, Clarke AJ, Beveridge TJ. Surface action of gentamicin on Pseudomonas aeruginosa. J Bacteriol. 175:1993;5798-5805.
36. Tankovic J, Perichon B, Duval J, Courvalin P. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother. 40:1996;2505-2510.
37. Hoshino K, Kitamura A, Morrissey I, Sato K, Kato J, Ikeda H. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother. 38:1994;2623-2627.
38. Finlay BB, Cossart P. Exploitation of mammalian host cell functions by bacterial pathogens. of special interest Science. 276:1997;719-725 The interaction between bacteria and host cells is reviewed. The significance of signal transduction pathways, cytoskeletal rearrangements, and vacuolar trafficking are examined.
39. Finlay BB, Falkow S. Common themes is microbial pathogenicity revisited. of special interest Microbiol Mol Biol Rev. 61:1997;136-169 This is an excellent review on genetic strategies used by bacteria to cause infections. Productin of toxins, adherence and invasion of host cells, mechanisms of survival of intracellular pathogens are examined.
40. Service RF. Antibiotics that resist resistance. Science. 270:1995;724-727.
41. Groisman EA, Ochman H. Pathogenicity islands: bacterial evolution in quantum leaps. Cell. 87:1996;791-794.
42. Strauss EJ, Falkow S. Microbial pathogenesis: genomics and beyond. Science. 276:1997;707-712.
43. Maiden MCJ, Malorny B, Achtman M. A global gene pool in the Neisseriae. Mol Microbiol. 21:1996;1297-1298.
44. Hensel M, Shea JE, Gleeson C, Jones MD, Dalton E, Holden DW. Simultaneous identification of bacterial virulence genes by negative selection. Science. 269:1995;400-403.
45. Mahan MJ, Slauch JM, Mekalanos JJ. Selection of bacterial virulence genes that are specifically induced in host tissues. Science. 259:1993;686-688.
46. Patchett AA. Excursions in drug discovery. J Med Chem. 36:1993;2051-2058.
47. Hirschmann R. Medicinal chemistry in the golden age of biology: lessons from steroid and peptide research. Int Ed Angew Chem. 30:1991;1278-1301.
48. Bertrand JA, Auger G, Fanchon E, Martin L, Blanot D, van Heijenoort J, Dideberg O. Crystal structure of UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase from Escherichia coli. EMBO J. 16:1997;3416-3425.
49. Fan C, Park IS, Walsh CT, Knox JR. D-Alanine:D-alanine ligase: phosphonate and phosphinate intermediates with wild type and the Y216F mutant. Biochem. 36:1997;2531-2538.
50. Agrawal RK, Penczek P, Grassucci RA, Li Y, Leith A, Nierhaus KH, Frank J. Direct visualization of A-, P-, and E-site transfer RNAs in the Escherichia coli ribosome. Science. 271:1996;1000-1002.
51. Marshall BJ. Treatment strategies for Helicobacter pylori infections. Gastroenterol Clin North Am. 22:1993;183-198.
52. Trias J. Antibiotic transport in mycobacteria. Georgopapapdakou N. Drug Transport in Antimicrobial and Anticancer Chemotherapy. 1995;269-288 Marcel Dekker, New York.
53. Horsburg JR. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med. 324:1991;1332-1338.
54. Pierce M, Crampon S, Henry D, Heifets L, LaMarca A, Montecalvo M, Wormser GP, Jablonowski H, Jemsek J, Cynamon M, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 335:1996;384-391.
55. Havlir DV, Dube MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Lavelle JP, White AC, Witt MD, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med. 335:1996;392-398.
56. Fodor S. How genes will revolutionise health care. Curr Opin Biotechnol. 1997.
57. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinovir. of special interest N Engl J Med. 334:1996;1674-1675 This is one of the first published accounts of changes in AIDS opportunistic infections after treatment with HIV protease inhibitor, and shows that the incidence of AIDS-associated infections can follow the success of HIV therapy in AIDs patients.